An investigation into cellular components in bacteria has unexpectedly uncovered a feature with relevance across many life ...

North America remains the largest contributor to the global exosomes market, driven by substantial R&D investments, expanding clinical trials, and strong collaborations between biotechnology companies ...

Obe-cel demonstrates high remission rates in pediatric patients with high-risk r/r B-ALL with overall response rate (ORR) of 95.5%; low rates of ...

BOAS is a platform for building multivalent viral protein immunogens without a scaffold, such as a nanoparticle, to elicit broad influenza vaccine responses.